| 000 | 01729 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250513200222.0 | ||
| 264 | 0 | _c20000124 | |
| 008 | 200001s 0 0 eng d | ||
| 022 | _a0269-9370 | ||
| 024 | 7 |
_a10.1097/00002030-199912030-00002 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSavès, M | |
| 245 | 0 | 0 |
_aSevere hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe dEpidémiologie Clinique de Sida en Aquitaine (GECSA). _h[electronic resource] |
| 260 |
_bAIDS (London, England) _cDec 1999 |
||
| 300 |
_aF115-21 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAnti-HIV Agents _xadministration & dosage |
| 650 | 0 | 4 | _aChemical and Drug Induced Liver Injury |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFrance |
| 650 | 0 | 4 |
_aHIV Infections _xdrug therapy |
| 650 | 0 | 4 |
_aHIV Protease Inhibitors _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 |
_aReverse Transcriptase Inhibitors _xadministration & dosage |
| 650 | 0 | 4 | _aRisk Factors |
| 700 | 1 | _aVandentorren, S | |
| 700 | 1 | _aDaucourt, V | |
| 700 | 1 | _aMarimoutou, C | |
| 700 | 1 | _aDupon, M | |
| 700 | 1 | _aCouzigou, P | |
| 700 | 1 | _aBernard, N | |
| 700 | 1 | _aMercié, P | |
| 700 | 1 | _aDabis, F | |
| 773 | 0 |
_tAIDS (London, England) _gvol. 13 _gno. 17 _gp. F115-21 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/00002030-199912030-00002 _zAvailable from publisher's website |
| 999 |
_c10553839 _d10553839 |
||